Norbert Hilf

Norbert Hilf has advanced mRNA-loaded dendritic cell vaccines for cancer immunotherapy, demonstrating in the GAPVAC trial that personalized multi-peptide and mRNA-loaded DC vaccines can induce robust anti-tumor immune responses in glioblastoma patients. His work has shown that mRNA loading provides advantages over peptide loading by enabling MHC class I and II presentation from a single transcript. He has contributed to developing scalable mRNA-DC vaccine manufacturing processes. His clinical research has advanced DC vaccines for difficult-to-treat brain tumors.